KP415 oral capsule
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout KP415 oral capsule
KP415 oral capsule is a phase 3 stage product being developed by Zevra Therapeutics for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT03460652. Target conditions include ADHD.
What happened to similar drugs?
10 of 20 similar drugs in ADHD were approved
Approved (10) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03460652 | Phase 3 | Completed |
Competing Products
20 competing products in ADHD